Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

Quan-shun Wang; Yao Wang; Hai-yan Lv; Qing-wang Han; Hui Fan; Bo Guo; Li-Li Wang; Wei-dong Han

doi:10.1038/mt.2014.164

journal article Open Access Jan 01, 2015

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

Quan-shun Wang Yao Wang

Hai-yan Lv Qing-wang Han Hui Fan Bo Guo

Li-Li Wang

Wei-dong Han

Molecular Therapy Vol. 23 No. 1 pp. 184-191 · Elsevier BV

View at Publisher Save 10.1038/mt.2014.164

Topics

No keywords indexed for this article. Browse by subject →

References

34

[1]

Döhner "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet" Blood (2010) 10.1182/blood-2009-07-235358

[2]

Creutzig "Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel" Blood (2012) 10.1182/blood-2012-03-362608

[3]

Tettamanti "Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors" Immunol Lett (2013) 10.1016/j.imlet.2013.09.013

[4]

Pearce "AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML" Blood (2006) 10.1182/blood-2005-06-2325

[5]

Nakahata "Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers" Leuk Lymphoma (1994) 10.3109/10428199409049629

[6]

Taussig "Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia" Blood (2005) 10.1182/blood-2005-03-1072

[7]

Griffin "A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells" Leuk Res (1984) 10.1016/0145-2126(84)90001-8

[8]

Dinndorf "Expression of normal myeloid-associated antigens by acute leukemia cells" Blood (1986) 10.1182/blood.v67.4.1048.1048

[9]

Kung Sutherland "SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML" Blood (2013) 10.1182/blood-2013-03-491506

[10]

Nand "A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia" Blood (2013) 10.1182/blood-2013-06-506592

[11]

Rowe "Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug" Blood (2013) 10.1182/blood-2013-03-490482

[12]

Hinrichs "Exploiting the curative potential of adoptive T-cell therapy for cancer" Immunol Rev (2014) 10.1111/imr.12132

[13]

Grupp "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia" N Engl J Med (2013) 10.1056/nejmoa1215134

[14]

Kalos "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia" Sci Transl Med (2011) 10.1126/scitranslmed.3002842

[15]

Kochenderfer "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells" Blood (2012) 10.1182/blood-2011-10-384388

[16]

Dutour "In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia" Adv Hematol (2012) 10.1155/2012/683065

[17]

Marin "Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors" Haematologica (2010) 10.3324/haematol.2010.026310

[18]

Pizzitola "Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo" Leukemia (2014) 10.1038/leu.2014.62

[19]

Sievers "Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse" J Clin Oncol (2001) 10.1200/jco.2001.19.13.3244

[20]

Kharfan-Dabaja "Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis" Br J Haematol (2013) 10.1111/bjh.12528

[21]

Wang "CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo" Exp Hematol (2013) 10.1016/j.exphem.2012.10.014

[22]

Laszlo "The past and future of CD33 as therapeutic target in acute myeloid leukemia" Blood Rev (2014) 10.1016/j.blre.2014.04.001

[23]

McKoy "Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project" Leuk Res (2007) 10.1016/j.leukres.2006.07.005

[24]

Larson "Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence" Cancer (2005) 10.1002/cncr.21326

[25]

Maniecki "Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?" Leuk Res (2011) 10.1016/j.leukres.2011.01.025

[26]

Nishimura "In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity" Blood (2008) 10.1182/blood-2007-06-092817

[27]

Hernández-Caselles "A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing" J Leukoc Biol (2006) 10.1189/jlb.0205096

[28]

Hauswirth "Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells" Eur J Clin Invest (2007) 10.1111/j.1365-2362.2007.01746.x

[29]

Cowan "Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin" Front Biosci (Landmark Ed) (2013) 10.2741/4181

[30]

Jedema "Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity" Leukemia (2004) 10.1038/sj.leu.2403205

[31]

Landau "Clonal evolution in hematological malignancies and therapeutic implications" Leukemia (2014) 10.1038/leu.2013.248

[32]

Zeijlemaker "Tumor heterogeneity makes AML a “moving target” for detection of residual disease" Cytometry B Clin Cytom (2014) 10.1002/cyto.b.21134

[33]

Introna "Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study" Haematologica (2007) 10.3324/haematol.11132

[34]

Linn "The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies" Bone Marrow Transplant (2012) 10.1038/bmt.2011.202

Cited By

376

Active Rac1‐Mediated Bone Marrow Retention Enhances CD33 CAR ‐T Cell Efficacy Against CD33 + Leukemia Cells

Shangshang Wang, Le Li · 2026

The FASEB Journal

CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs

F. Rahbarizadeh, D. Ahmadvand · 2019

Advanced Drug Delivery Reviews

Metrics

376

Citations

34

References

Details

Published: Jan 01, 2015
Vol/Issue: 23(1)
Pages: 184-191
License: View

Authors

Qufu Normal University

Beijing National Laboratory for Condensed Matter Physics, Institute of Physics, The Chinese Academy of Sciences, Beijing 100190, China.

W

Wei-dong Han

Cite This Article

Quan-shun Wang, Yao Wang, Hai-yan Lv, et al. (2015). Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia. Molecular Therapy, 23(1), 184-191. https://doi.org/10.1038/mt.2014.164

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

You May Also Like